N
AZN icon

Natixis’s AstraZeneca AZN Stock Holding History

Natixis’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-36,442
Closed -$5.22M – 986
2023
Q2 		$5.22M Buy
36,442
+36,124
+11,360% +$5.32M 0.04% 289
2023
Q1 		$44.1K Sell
318
-2,007
-86% -$270K ﹤0.01% 842
2022
Q4 		$315K Buy
+2,325
New +$292K ﹤0.01% 771
2021
Q3 		– Sell
-375,026
Closed -$44.9M – 1194
2021
Q2 		$44.9M Buy
375,026
+89,960
+32% +$9.87M 0.2% 101
2021
Q1 		$28.4M Buy
285,066
+249,122
+693% +$25M 0.09% 205
2020
Q4 		$3.59M Buy
+35,944
New +$3.81M 0.01% 577

Other funds holding AZN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
GQG Partners
GQG Partners Ft. Lauderdale, Florida $53.8B AUM 19.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Natixis's AZN Position: Q3 2023 in Review

Natixis sold out of AstraZeneca (AZN) in Q3 2023, closing a stake of 36,442 shares — an estimated $5.22M sold.

Natixis first reported a position in AZN in Q4 2020 and held it in 6 quarters. The position peaked at $44.9M in Q2 2021. 1,073 funds tracked by Wall St. Rank hold AZN as of Q3 2023.

  • Natixis reported no remaining AstraZeneca position as of Q3 2023 after selling out during the quarter.
  • Natixis sold 36,442 AstraZeneca shares in Q3 2023, an estimated $5.22M.
  • Natixis first reported a position in AstraZeneca in Q4 2020 and held it in 6 quarters.
  • Natixis's AstraZeneca position peaked at $44.9M in Q2 2021.
  • 1,073 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2023.

Based on Natixis's 13F filing for Q3 2023, filed 14 Nov 2023.